Cargando…

Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients

BACKGROUND: The programme death ligand1 and its receptor (PD-1/PD-L1) interaction is a target for blockage by immunotherapy that uses the body’s own immune system. Some studies show that PD-L1 expressing tumours are also more aggressive with poor prognosis. This study evaluated the immunohistochemic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Omenai, Sebastian A., Ajani, Mustapha A., Okolo, Clement A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827435/ https://www.ncbi.nlm.nih.gov/pubmed/35139126 http://dx.doi.org/10.1371/journal.pone.0263615

Ejemplares similares

Histomorphological assessment of non-neoplastic renal diseases at autopsy: an institutional experience in Southwestern Nigeria
por: Omenai, Sebastian A, et al.
Publicado: (2021)

Histopathological profile of childhood thyroid carcinoma in Ibadan, Southwestern Nigeria
por: Ajani, Mustapha A, et al.
Publicado: (2020)

Hormonal Receptor Expression in Endometrial Carcinoma: A Retrospective Immunohistochemical Study in a Nigerian Tertiary Hospital
por: Odetola, Segun Samson, et al.
Publicado: (2020)

CERVICAL LYMPHADENOPATHY IN IBADAN, NIGERIA
por: Aramide, KO, et al.
Publicado: (2017)

Childhood ovarian neoplasms in Ibadan, South-western Nigeria
por: Ajani, Mustapha Akanji, et al.
Publicado: (2016)

Malignant ameloblastoma: a challenging diagnosis
por: Salami, Ayodeji, et al.
Publicado: (2018)

Programmed death ligand‐1 expression in gastrointestinal cancer: Clinical significance and future challenges
por: Yamashita, Kohei, et al.
Publicado: (2020)

BILATERAL GANGLIONIC HAEMORRHAGIC STROKE COMPLICATING SUSPECTED MENINGOCOCCAEMIA: A CASE REPORT
por: Omenai, S.A., et al.
Publicado: (2020)

Histopathology of Head and Neck Lymphomas in Ibadan
por: Ajani, Mustapha A., et al.
Publicado: (2020)

Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
por: Reddy, Opal L., et al.
Publicado: (2017)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma
por: Park, Dong-Jun, et al.
Publicado: (2021)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy
por: Gutic, Bojana, et al.
Publicado: (2023)

Alpha-Fetoprotein- and CD40Ligand-Expressing Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma
por: Vogt, Annabelle, et al.
Publicado: (2021)

SECONDARY OVARIAN NEOPLASMS IN A TERTIARY HOSPITAL IN SOUTHWESTERN NIGERIA
por: Ajani, M.A., et al.
Publicado: (2019)

Surrogate endpoints and competing risk of death in cardiac arrest research
por: McCredie, Victoria A., et al.
Publicado: (2016)

Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability
por: Montella, Marco, et al.
Publicado: (2022)

The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints
por: Giuffrida, Paolo, et al.
Publicado: (2022)

Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer
por: Yamashita, Kohei, et al.
Publicado: (2020)

Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer
por: Dong, Zhengwei, et al.
Publicado: (2020)

Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
por: Jiang, Yao, et al.
Publicado: (2023)

Case report: Advanced primary squamous cell carcinoma in the periampullary area with upregulation of programmed cell death-ligand 1 expression and response to sintilimab immunotherapy
por: Wang, Baoshan, et al.
Publicado: (2023)

The impact of Jade Goody's diagnosis and death on the NHS Cervical Screening Programme
por: Lancucki, L, et al.
Publicado: (2012)

Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients
por: Yang, Haitang, et al.
Publicado: (2021)

Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels
por: Kemp, Troy J., et al.
Publicado: (2012)

Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells
por: Sukowati, Caecilia H C, et al.
Publicado: (2021)

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
por: Fay, André P, et al.
Publicado: (2015)

Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma
por: Li, Ying-Fei, et al.
Publicado: (2017)

Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis
por: Batur, Sebnem, et al.
Publicado: (2020)

Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment
por: Li, Aixin, et al.
Publicado: (2022)

The Role of Immune Correlates and Surrogate Markers in the Development of Vaccines and Immunotherapies for Plague
por: Williamson, E. D.
Publicado: (2012)

Changing Cause of Death Profile in Morocco: The Impact of Child-survival Programmes
por: Garenne, Michel, et al.
Publicado: (2007)

Programmed death-ligand 1 expression in rectal cancer
por: Jomrich, G., et al.
Publicado: (2016)

Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells
por: Chen, Zhifang, et al.
Publicado: (2016)

Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer
por: Zhang, Ying, et al.
Publicado: (2017)

Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy
por: Wu, Chao, et al.
Publicado: (2010)

Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer
por: Li, Xintong, et al.
Publicado: (2022)

Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors
por: Kareff, Samuel A., et al.
Publicado: (2021)

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oelfo30d2hdfas8supun7serv2